Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline

Crown offer of $3.65 per share is the only offer available to Revance stockholders Crown offer unanimously approved by the Revance Board of Directors Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender  Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), tod ...